BR112018004175B8 - Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto - Google Patents
Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito compostoInfo
- Publication number
- BR112018004175B8 BR112018004175B8 BR112018004175A BR112018004175A BR112018004175B8 BR 112018004175 B8 BR112018004175 B8 BR 112018004175B8 BR 112018004175 A BR112018004175 A BR 112018004175A BR 112018004175 A BR112018004175 A BR 112018004175A BR 112018004175 B8 BR112018004175 B8 BR 112018004175B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pyrazolo
- her2
- pharmaceutical composition
- therapeutic uses
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 Pyrazolo[3,4-d]pyrimidine compound Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
composto pirazolo[3,4-d]pirimidina, composição farmacêutica, inibidor de her2 e agente antitumor contendo o dito composto e usos terapêuticos do dito composto. para fornecer um novo composto tendo um efeito inibitório sobre her2 e tendo um efeito citostático. também se destina a fornecer um medicamento útil na prevenção e/ou tratamento de uma doença que envolve her2, particularmente, câncer, na base do efeito inibitório sobre her2. a presente invenção fornece um composto de fórmula (i) em que x, y, z1, z2, z3, z4, w, n, r1, r2 e r3 têm significados conforme definidos na presente especificação, ou um sal deste.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015172354 | 2015-09-01 | ||
| JP2015-172354 | 2015-09-01 | ||
| PCT/JP2016/075380 WO2017038838A1 (ja) | 2015-09-01 | 2016-08-31 | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112018004175A2 BR112018004175A2 (pt) | 2018-09-25 |
| BR112018004175B1 BR112018004175B1 (pt) | 2023-07-25 |
| BR112018004175B8 true BR112018004175B8 (pt) | 2023-10-31 |
Family
ID=58188946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018004175A BR112018004175B8 (pt) | 2015-09-01 | 2016-08-31 | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9920060B2 (pt) |
| EP (1) | EP3345907B1 (pt) |
| JP (1) | JP6141568B1 (pt) |
| KR (1) | KR102075886B1 (pt) |
| CN (1) | CN108349981B (pt) |
| AU (1) | AU2016317521B2 (pt) |
| BR (1) | BR112018004175B8 (pt) |
| CA (1) | CA2997051C (pt) |
| DK (1) | DK3345907T3 (pt) |
| ES (1) | ES2799520T3 (pt) |
| HK (1) | HK1257146A1 (pt) |
| MX (1) | MX2018002520A (pt) |
| MY (1) | MY191938A (pt) |
| PH (1) | PH12018500437A1 (pt) |
| PL (1) | PL3345907T3 (pt) |
| PT (1) | PT3345907T (pt) |
| RU (1) | RU2705579C2 (pt) |
| SG (1) | SG11201801365YA (pt) |
| TW (1) | TWI659957B (pt) |
| WO (1) | WO2017038838A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| SG11201806930PA (en) | 2016-02-23 | 2018-09-27 | Taiho Pharmaceutical Co Ltd | Novel condensed pyrimidine compound or salt thereof |
| KR102674711B1 (ko) * | 2017-02-28 | 2024-06-12 | 다이호야쿠힌고교 가부시키가이샤 | 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CN106967303A (zh) * | 2017-05-02 | 2017-07-21 | 杭州福莱蒽特精细化工有限公司 | 一种艳色兰偶氮染料及其制备方法和应用 |
| MA53509A (fr) * | 2018-08-29 | 2021-07-07 | Taiho Pharmaceutical Co Ltd | Agent thérapeutique contenant un composé pyrazolo[3,4-d]pyrimidine comme ingrédient actif |
| US20210332056A1 (en) * | 2018-08-29 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Crystal of pyrazolo[3,4-d]pyrimidine |
| DK3909584T5 (da) * | 2019-01-11 | 2024-08-05 | Taiho Pharmaceutical Co Ltd | Pyrimidinforbindelse eller salt deraf |
| CN113336760B (zh) * | 2020-02-18 | 2022-11-04 | 深圳市塔吉瑞生物医药有限公司 | 取代的酰胺衍生物及其组合物及用途 |
| CN111440138A (zh) * | 2020-04-30 | 2020-07-24 | 中国林业科学研究院林产化学工业研究所 | 具有hdac抑制和抗肿瘤活性的新型漆酚基异羟肟酸衍生物的合成方法 |
| TW202216717A (zh) * | 2020-07-15 | 2022-05-01 | 日商大鵬藥品工業股份有限公司 | 嘧啶化合物之結晶 |
| MX2023000693A (es) | 2020-07-15 | 2023-02-13 | Taiho Pharmaceutical Co Ltd | Inhibidor de egfr. |
| AU2021308045B2 (en) | 2020-07-15 | 2024-06-20 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
| MX2023003362A (es) | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| US20230295167A1 (en) * | 2020-10-05 | 2023-09-21 | Dana-Farber Cancer Institute, Inc. | Potent and selective inhibitors of her2 |
| CA3198202A1 (en) | 2020-10-09 | 2022-04-14 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| IL314308A (en) * | 2022-01-25 | 2024-09-01 | Ksq Therapeutics Inc | Ubiquitin-specific processing protease 1 (USP1) inhibitors for the treatment of solid tumors |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CN114736207B (zh) * | 2022-04-28 | 2023-03-31 | 武汉九州钰民医药科技有限公司 | 一种小分子her2抑制剂的制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE403428T1 (de) * | 2003-06-27 | 2008-08-15 | Pfizer Prod Inc | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| EP1968979A2 (en) * | 2005-12-08 | 2008-09-17 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2560007A1 (en) * | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification of bruton's tyrosine kinase inhibitors |
| MX347040B (es) * | 2011-05-17 | 2017-04-10 | Principia Biopharma Inc | Inhibidores de tirosina-cinasas. |
| JP2014520863A (ja) * | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| PL2657233T3 (pl) | 2012-01-19 | 2015-01-30 | Taiho Pharmaceutical Co Ltd | 3,5-dipodstawiony związek alkinylobenzenowy i jego sól |
| NO2947086T3 (pt) * | 2013-08-12 | 2018-06-02 | ||
| WO2015023703A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmacyclics, Inc. | Methods for the treatment of her2 amplified cancer |
-
2016
- 2016-08-31 BR BR112018004175A patent/BR112018004175B8/pt active IP Right Grant
- 2016-08-31 ES ES16841868T patent/ES2799520T3/es active Active
- 2016-08-31 RU RU2018111439A patent/RU2705579C2/ru active
- 2016-08-31 JP JP2017513832A patent/JP6141568B1/ja active Active
- 2016-08-31 MY MYPI2018700648A patent/MY191938A/en unknown
- 2016-08-31 CA CA2997051A patent/CA2997051C/en active Active
- 2016-08-31 EP EP16841868.9A patent/EP3345907B1/en active Active
- 2016-08-31 PL PL16841868T patent/PL3345907T3/pl unknown
- 2016-08-31 CN CN201680063691.7A patent/CN108349981B/zh active Active
- 2016-08-31 WO PCT/JP2016/075380 patent/WO2017038838A1/ja active Application Filing
- 2016-08-31 MX MX2018002520A patent/MX2018002520A/es active IP Right Grant
- 2016-08-31 AU AU2016317521A patent/AU2016317521B2/en active Active
- 2016-08-31 SG SG11201801365YA patent/SG11201801365YA/en unknown
- 2016-08-31 TW TW105127978A patent/TWI659957B/zh active
- 2016-08-31 KR KR1020187009035A patent/KR102075886B1/ko active IP Right Grant
- 2016-08-31 PT PT168418689T patent/PT3345907T/pt unknown
- 2016-08-31 DK DK16841868.9T patent/DK3345907T3/da active
-
2017
- 2017-04-20 US US15/492,442 patent/US9920060B2/en active Active
-
2018
- 2018-02-28 PH PH12018500437A patent/PH12018500437A1/en unknown
- 2018-03-16 US US15/922,980 patent/US10329300B2/en active Active
- 2018-12-21 HK HK18116402.8A patent/HK1257146A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| BR112014019052A8 (pt) | Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
| CR7899A (es) | Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa | |
| WO2017128917A8 (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CL2019001658A1 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112019007763A2 (pt) | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2742 DE 25/07/2023, QUANTO AO ITEM (54) TITULO. |